about
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.Splicing factor and exon profiling across human tissues.Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation.Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapseAF1q/MLLT11 regulates the emergence of human prothymocytes through cooperative interaction with the Notch signaling pathwayBone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cellsPrognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLHigh imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patientsKinetics of the establishment of HIV-1 viral interference and comprehensive analysis of the contribution of viral genes.High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial.Dynamics of human prothymocytes and xenogeneic thymopoiesis in hematopoietic stem cell-engrafted nonobese diabetic-SCID/IL-2rγnull mice.Variation of liver SUV on (18)FDG-PET/CT studies in women with breast cancer.Co-infection, super-infection and viral interference in HIV.Association between Parkinson's disease and the HLA-DRB1 locus.Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity.Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT.Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.The rising prevalence of chronic myeloid leukemia in France.Multiple imputation for competing risks regression with interval-censored data18F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional StagingUsing healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemiasMDA5+ Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN-κ Transcript
P50
Q30490577-28CE4B3E-08E2-4FC2-8297-F0F5C5FC0D29Q33871191-16CB729E-C292-4985-B880-DA14B97E65C2Q34798117-127BB48B-399B-48C0-956F-F91805DA2BE9Q35102275-0648B1B2-494D-45BB-B6A0-14B3754C1B27Q35172457-F19AA05A-99DA-4B7C-9BD0-4DCFCD435C82Q36083918-3DFB6A03-CFC7-4025-A202-94EB40B04B7FQ36232141-42EF4C3E-6291-436D-AE83-A565756D4CC3Q36476568-3439FC81-0776-4116-9C23-5DF16718B260Q37376595-DF54F029-E2E4-4F08-A45C-55C41A1D3F8CQ37381574-A9A1EB89-28B3-4084-8B9A-279293B274DCQ38825125-DD6FAAC5-BE3F-46B7-AA6F-4B4D028097ECQ41441391-1F68C0A8-9C42-40EB-A0B0-290C063B7F21Q43767904-B62889EA-6F1E-4833-8485-A7E513D1C230Q44723938-954627E2-2B07-4310-AE44-26512348CF49Q47133458-189331FD-318C-418A-B7B6-F8D21A9C258FQ47374004-961F0E49-F3AD-40B9-9DA4-17F02EC9CD3EQ48318111-AD8BA273-5575-4E29-87BC-00ECC9C947B4Q53140875-C79ACAA2-EB31-44C4-B02A-6238FD00B320Q53180618-2A139752-C8BA-47F4-9731-771D378A35D8Q53205042-4A844FB1-92AB-455B-B5E2-90E315135ED8Q54979614-9218AD88-E088-479E-9962-4DFC4CF7B4F4Q56915011-44108A15-0705-48B5-B0CB-5869B1E17D97Q56915020-6E1668A8-A522-4E82-9EAD-F7B2B95AE7A5Q64968207-58F317C7-8E21-4971-A416-611A88DC90DFQ91375266-2BCA481E-3B12-4300-A2DD-7E25D3A9B066Q92755771-B0673ACE-D66B-4036-B5AF-B1734B9A368D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marc Delord
@ast
Marc Delord
@en
Marc Delord
@es
Marc Delord
@nl
Marc Delord
@sl
type
label
Marc Delord
@ast
Marc Delord
@en
Marc Delord
@es
Marc Delord
@nl
Marc Delord
@sl
prefLabel
Marc Delord
@ast
Marc Delord
@en
Marc Delord
@es
Marc Delord
@nl
Marc Delord
@sl
P106
P21
P31
P3835
marc-delord
P496
0000-0002-0455-6749